Abstract:Aim: Limited literature is available regarding the treatment of recurrent surgery- and radiation-refractory meningioma, and it primarily examines the treatment of low-grade (WHO grade 1) meningioma. Data regarding systemic therapy for recurrent high-grade meningioma are sparse. A retrospective case series of patients with recurrent WHO grade 2/3 meningioma treated with IFN-α following progression after surgery, radiotherapy and hydroxyurea was carried out, with the primary study objective of overall response rate, and median and 6-month progression-free survival (PFS). Patients & methods: 35 patients (28 women and 17 men; median age 63 years; range: 36-86 years) with recurrent high-grade meningioma (WHO grade 2 [n = 22] or 3 [n = 13]) were treated with IFN-α (10 million units/m(2)) subcutaneously every 2 days; one cycle was operationally defined as 4 weeks of IFN-α. Patients had progressed radiographically after prior therapy with surgery (35 out of 35), radiotherapy (35 out of 35; external-beam radiotherapy: 35 out of 35; and stereotactic radiotherapy: 34 out of 35) and hydroxyurea chemotherapy (35 out of 35). One patient was also treated with a somatostatin analog before initiating IFN-α treatment. Results: Patients received one to 13 cycles (median: three) of IFN-α with moderate toxicity (100% of patients manifested grades 1-3 toxicity, of which only 20% were grade 3). There were no radiographic responses, 63% of patients had stable disease and 37% manifested progressive disease at first evaluation. PFS was 17% at 6 months (95% CI: 0.07-0.31; median PFS: 12 weeks; 95% CI: 8-20 weeks; range: 4-52 weeks). Following progression on IFN-α, the majority of patients (60%) were subsequently treated on an alternative therapy. Conclusion: In this large retrospective series, IFN-α was moderately toxic, but appeared to have limited activity in patients with recurrent high-grade meningiomas.

Medical treatment of recurrent meningiomas

Nonsurgical treatment options in the management of intracranial meningiomas

Guidelines to the treatment of meningioma

Surgical Treatment of Recurrent Parasagittal Meningiomas

Current treatment options for meningioma

[Meningioma: management of the most common brain tumour]

Multimodality Therapy of Patients with Refractory Meningiomas

Current experimental therapies for atypical and malignant meningiomas

High Grade Meningiomas: Current Therapy Based on Tumor Biology

Medical Management of Meningiomas

Management of Recurrent Meningiomas: State of the Art and Perspectives

Current immunotherapy techniques in meningioma

IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series

Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort

Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up

Predictors of Treatment Response and Survival Outcomes in Meningioma Recurrence with Atypical or Anaplastic Histology

Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms

Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues

Related mechanisms, current treatments, and new perspectives in meningioma

Ctni-80. 177Lu-Dotatate In Patients With Recurrent Meningioma

Radiotherapy in the Treatment of Meningiomas